H White

Summary

Country: New Zealand

Publications

  1. doi request reprint Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial
    C K Wong
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Heart 95:276-82. 2009
  2. ncbi request reprint Withdrawal of statins increases event rates in patients with acute coronary syndromes
    Christopher Heeschen
    University Hospital Frankfurt, Germany
    Circulation 105:1446-52. 2002
  3. doi request reprint The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, 1030, New Zealand
    Curr Atheroscler Rep 13:132-7. 2011
  4. doi request reprint HORIZONS trial: a step forward for primary percutaneous coronary intervention
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Level 3, Building 32, Private Bag 92 024, Auckland 1030, New Zealand
    Expert Rev Cardiovasc Ther 7:125-9. 2009
  5. ncbi request reprint Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 52:807-14. 2008
  6. ncbi request reprint Universal MI definition update for cardiovascular disease
    Harvey White
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland, 1142, New Zealand
    Curr Cardiol Rep 16:492. 2014
  7. pmc Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Heart Assoc 2:e000360. 2013
  8. pmc Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction
    Naylin Bissessor
    Green Lane Cardiovascular Research Unit, Auckland City Hospital, Auckland, New Zealand
    Vasc Health Risk Manag 3:425-30. 2007
  9. doi request reprint Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital and Auckland University, Auckland, New Zealand Electronic address
    J Am Coll Cardiol 63:345-54. 2014
  10. ncbi request reprint Higher mortality in women undergoing coronary artery bypass grafting
    Tom Kai Ming Wang
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 126:25-31. 2013

Detail Information

Publications115 found, 100 shown here

  1. doi request reprint Relationship of QRS duration at baseline and changes over 60 min after fibrinolysis to 30-day mortality with different locations of ST elevation myocardial infarction: results from the Hirulog and Early Reperfusion or Occlusion-2 trial
    C K Wong
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Heart 95:276-82. 2009
    ..To discern if the prognostic meaning of QRS prolongation differs according to the location of ST elevation acute myocardial infarction..
  2. ncbi request reprint Withdrawal of statins increases event rates in patients with acute coronary syndromes
    Christopher Heeschen
    University Hospital Frankfurt, Germany
    Circulation 105:1446-52. 2002
    ..Withdrawal of chronic statin treatment during acute coronary syndromes may impair vascular function independent of lipid-lowering effects and thus increase cardiac event rate...
  3. doi request reprint The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, 1030, New Zealand
    Curr Atheroscler Rep 13:132-7. 2011
    ..Two large phase III clinical trials that are currently in progress will determine whether darapladib will reduce the risk of myocardial infarction, stroke, and cardiovascular death by stabilizing atherosclerotic plaques...
  4. doi request reprint HORIZONS trial: a step forward for primary percutaneous coronary intervention
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Level 3, Building 32, Private Bag 92 024, Auckland 1030, New Zealand
    Expert Rev Cardiovasc Ther 7:125-9. 2009
    ..Bivalirudin is an attractive antithrombotic choice in patients undergoing primary PCI...
  5. ncbi request reprint Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Tria
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 52:807-14. 2008
    ..This study was designed to determine the impact of bivalirudin on 1-year outcomes in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI)...
  6. ncbi request reprint Universal MI definition update for cardiovascular disease
    Harvey White
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland, 1142, New Zealand
    Curr Cardiol Rep 16:492. 2014
    ..In clinical practice, trials, and registries, different definitions are used. There is a need for consistency with regard to the definition of MI and the universal definition should be implemented...
  7. pmc Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Heart Assoc 2:e000360. 2013
    ..Lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are associated with coronary heart disease (CHD) in healthy individuals and in patients who have had ischemic events...
  8. pmc Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction
    Naylin Bissessor
    Green Lane Cardiovascular Research Unit, Auckland City Hospital, Auckland, New Zealand
    Vasc Health Risk Manag 3:425-30. 2007
    ..This review examines the role of valsartan in left ventricular dysfunction post myocardial infarction. We also discuss pharmacokinetics, dosing, side effects, and usage in the elderly...
  9. doi request reprint Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital and Auckland University, Auckland, New Zealand Electronic address
    J Am Coll Cardiol 63:345-54. 2014
    ..This study sought to assess whether baseline and change in contemporary sensitive troponin I (TnI) levels predicts coronary heart disease (CHD) death and myocardial infarction (MI), and to determine the effects of pravastatin on TnI levels...
  10. ncbi request reprint Higher mortality in women undergoing coronary artery bypass grafting
    Tom Kai Ming Wang
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 126:25-31. 2013
    ..We compared characteristics and outcomes of coronary artery bypass grafting (CABG) by sex...
  11. ncbi request reprint Lack of relationship between obesity and mortality or morbidity after coronary artery bypass grafting
    Tom Kai Ming Wang
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 126:56-65. 2013
    ..Conflicting results have been reported regarding relationships between body mass index (BMI) and outcomes after coronary artery bypass grafting (CABG). We compared outcomes of CABG patients by BMI categories...
  12. ncbi request reprint Maori have worse outcomes after coronary artery bypass grafting than Europeans in New Zealand
    Tom Kai Ming Wang
    Green Lane Cardiovascular Service, Auckland City Hospital Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 126:12-22. 2013
    ..We compared characteristics and outcomes of coronary artery bypass grafting (CABG) between Maori and Europeans in New Zealand...
  13. ncbi request reprint Myocardial infarction following sclerotherapy in a patient with a patent foramen ovale
    Timothy A C Snow
    Green Lane Cardiovascular Service, Auckland City Hospital, Level 3, Building 32, Private Bag 92024, Victoria St West, Auckland 1142, New Zealand
    N Z Med J 125:64-7. 2012
    ..It is believed that microemboli crossed the PFO as a result of the procedure and caused coronary artery embolisation, resulting in the symptoms, electrocardiographic and biochemical evidence of myocardial infarction...
  14. pmc Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 163:563-71. 2012
    ..There was no difference in the primary end point of death, reinfarction, or heart failure at 2.9 or 6-year mean follow-up. However, in patients randomized to PCI, there was a trend toward a higher rate of reinfarction...
  15. doi request reprint Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand
    Am Heart J 163:182-90.e4. 2012
    ....
  16. ncbi request reprint Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgen
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    J Am Coll Cardiol 51:1734-41. 2008
    ..The aim of this study was to compare outcomes in patients receiving consistent unfractionated heparin (UFH)/enoxaparin (ENOX) therapy and in those switched at randomization to bivalirudin monotherapy...
  17. doi request reprint Heart disease in Soweto: facing a triple threat
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Lancet 371:876-7. 2008
  18. ncbi request reprint We must use the knowledge that we have to treat patients with acute coronary syndromes
    Harvey D White
    Auckland City Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Circulation 109:698-700. 2004
  19. ncbi request reprint Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Eur Heart J 28:1066-71. 2007
    ..To determine the effects of age on outcomes in patients with STEMI treated with a strategy of enoxaparin (ENOX) vs. unfractionated heparin (UFH)...
  20. ncbi request reprint Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Arch Intern Med 167:239-45. 2007
    ..Target INRs are frequently not achieved, and the risk of death, bleeding, myocardial infarction (MI), and stroke or systemic embolism event (SEE) may be related to INR control...
  21. ncbi request reprint Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revas
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 152:1042-50. 2006
    ..The SYNERGY trial compared these agents in high-risk patients undergoing early invasive treatment. Enoxaparin was noninferior to UFH for the 30-day primary end point of death/myocardial infarction (MI), but modestly increased bleeding...
  22. ncbi request reprint Missed opportunities for better health outcomes in New Zealand
    Harvey White
    Greenlane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    N Z Med J 117:U1002. 2004
  23. ncbi request reprint Electrocardiographic findings in cardiogenic shock, risk prediction, and the effects of emergency revascularization: results from the SHOCK trial
    Harvey D White
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am Heart J 148:810-7. 2004
    ....
  24. ncbi request reprint PHARMAC and lack of funding for clopidogrel
    Harvey White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    N Z Med J 119:U1808. 2006
    ..We need to have a better process whereby New Zealanders can rapidly access new treatments...
  25. ncbi request reprint Adherence and outcomes: it's more than taking the pills
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1001, New Zealand
    Lancet 366:1989-91. 2005
  26. ncbi request reprint Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarct
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 112:3391-9. 2005
    ..Those with heart failure or impaired left ventricular left ventricular function after acute myocardial infarction have high complication and mortality rates. Little is known about outcomes with contemporary therapies in these patients...
  27. ncbi request reprint Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK)
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland 1030, New Zealand
    Circulation 112:1992-2001. 2005
    ..The objective of this analysis was to compare the effects of PCI and CABG on 30-day and 1-year survival in the SHOCK trial...
  28. ncbi request reprint Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial
    H White
    Cardiology Department, Green Lane Hospital, Auckland 1030, New Zealand
    Lancet 358:1855-63. 2001
    ..We did a randomised, open-label trial to compare the thrombin-specific anticoagulant, bivalirudin, with heparin in patients undergoing fibrinolysis with streptokinase for acute myocardial infarction...
  29. ncbi request reprint Rheumatic heart disease in indigenous populations
    Harvey White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Heart Lung Circ 19:273-81. 2010
    ..Involvement of Indigenous people in decision making, design, and implementation of primary and secondary prevention programs, is mandatory to reduce the unacceptably high rates of rheumatic heart disease...
  30. ncbi request reprint Hematomas of at least 5 cm and outcomes in patients undergoing elective percutaneous coronary intervention: insights from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 159:110-6. 2010
    ..Limited information is available on the incidence and clinical relevance of hematomas > or =5 cm in PCI patients...
  31. doi request reprint Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease
    Harvey White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 160:655-61. 2010
    ..Direct inhibition of this proinflammatory enzyme with darapladib may benefit CV patients when given as an adjunct to standard of care, including lipid-lowering and antiplatelet therapies...
  32. ncbi request reprint Will new higher-precision troponins lead to clarity or confusion?
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Curr Opin Cardiol 23:292-5. 2008
    ..Newer assays with higher precision for detection of troponin levels are about to enter clinical practice. The present review discusses the implications of the new assays for patients...
  33. doi request reprint Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, New Zealand
    Am Heart J 161:450-61. 2011
    ..Two phase 3 trials are evaluating the efficacy and safety of vorapaxar in patients presenting with non-ST-segment elevation acute coronary syndromes and in patients with documented atherothrombotic disease...
  34. doi request reprint Strategies to minimize bleeding complications of percutaneous coronary intervention
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Curr Opin Cardiol 24:273-8. 2009
    ..In this review, the importance of the association of bleeding with mortality and strategies to reduce bleeding with percutaneous coronary intervention are discussed...
  35. ncbi request reprint Pharmacological and clinical profile of bivalirudin in the treatment of patients with acute coronary syndrome
    Harvey D White
    Coronary Care and Green Lane Cardiovascular Research Unit, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Auckland 1030, New Zealand
    Expert Opin Drug Metab Toxicol 5:529-38. 2009
    ..Bivalirudin has also recently been investigated in patients with ST-elevation myocardial infarction (STEMI) treated with primary angioplasty and stenting. More than 27,000 patients were randomized in these trials...
  36. doi request reprint The use of intravenous enoxaparin in elective percutaneous coronary intervention in patients with renal impairment: results from the SafeTy and Efficacy of Enoxaparin in PCI patients, an internationaL randomized Evaluation (STEEPLE) trial
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 157:125-31. 2009
    ..5 or 0.75 mg/kg, n = 2,298) or activated clotting time-adjusted unfractionated heparin (UFH, n = 1,230), stratified according to planned glycoprotein IIb/IIIa inhibitor use...
  37. ncbi request reprint Candesartan and heart failure: the allure of CHARM
    Harvey D White
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Lancet 362:754-5. 2003
  38. ncbi request reprint Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?
    Harvey D White
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Lancet 362:755-7. 2003
  39. ncbi request reprint ACS patients in New Zealand experience significant delays to access cardiac investigations and revascularisation treatment especially when admitted to non-interventional centres: results of the second comprehensive national audit of ACS patients
    Chris Ellis
    Cardiology Department, Green Lane CVS Services, Level 3, Auckland City Hospital, Grafton, Auckland 1023, New Zealand
    N Z Med J 123:44-60. 2010
    ..To compare the management of acute coronary syndrome (ACS) patients presenting to interventional versus non-interventional New Zealand hospitals, with emphasis, on access delays for invasive assessment and revascularisation treatments...
  40. ncbi request reprint Initial Q waves accompanying ST-segment elevation at presentation of acute myocardial infarction and 30-day mortality in patients given streptokinase therapy: an analysis from HERO-2
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Lancet 367:2061-7. 2006
    ..Our aim was to assess whether the presence or absence of Q waves at presentation could be used as an indicator of the duration of acute myocardial infarction and predict mortality...
  41. ncbi request reprint Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    J Am Coll Cardiol 46:29-38. 2005
    ....
  42. ncbi request reprint Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery
    Alan F Merry
    Department of Cardiothoracic Surgery, Green Lane Hospital, Auckland, New Zealand
    Ann Thorac Surg 77:925-31; discussion 931. 2004
    ..We also assessed flow with angiography at 3 months using a modified Thombolysis in Myocardial Infarction (TIMI) grade in the grafted coronary arteries...
  43. ncbi request reprint Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions
    Harvey D White
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Expert Opin Pharmacother 3:777-88. 2002
    ..Bivalirudin is suitable for use as an alternative to heparin in the majority of patients undergoing PCI and in patients receiving streptokinase for acute MI...
  44. ncbi request reprint Patients admitted with an acute coronary syndrome (ACS) in New Zealand in 2007: results of a second comprehensive nationwide audit and a comparison with the first audit from 2002
    Chris Ellis
    Cardiology Department, Green Lane CVS Services, Level 3, Auckland City Hospital, Grafton, Auckland 1023, New Zealand
    N Z Med J 123:25-43. 2010
    ..To compare patient management in 2007 with the 1st NZ Cardiac Society ACS Audit from 2002...
  45. ncbi request reprint Carvedilol: use in chronic heart failure
    Robert Neil Doughty
    Department of Medicine, Faculty of Medical and Health Sciences, Level 12, Auckland Hospital Support Building, Park Road, Auckland, New Zealand
    Expert Rev Cardiovasc Ther 5:21-31. 2007
    ..This evidence-based treatment should be widely implemented to ensure that patients with heart failure receive appropriate medical therapy...
  46. pmc Clinical implications of the new definition of myocardial infarction
    John K French
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Heart 90:99-106. 2004
  47. ncbi request reprint Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques
    John J Edmond
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiol 97:947-51. 2006
    ....
  48. ncbi request reprint Relationship between initial white blood cell counts, stage of acute myocardial infarction evolution at presentation, and incidence of Thrombolysis In Myocardial Infarction-3 flow after streptokinase
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am Heart J 145:95-102. 2003
    ..The initial white cell counts in patients with acute myocardial infarction (AMI) may reflect the stage of AMI evolution, and may also be related to the efficacy of thrombolytic agents in recanalizing occluded epicardial arteries...
  49. ncbi request reprint Variation in blood levels of inflammatory markers related and unrelated to smoking cessation in women
    Christopher J K Hammett
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Prev Cardiol 10:68-75. 2007
    ..1; interquartile range -0.2, 0.9 mg/L), intercellular adhesion molecule 1 (+17+/-75 ng/mL), or CD40 ligand (+0.4+/-2.1 ng/mL). Most of the individual variation in inflammatory marker levels was unrelated to changes in smoking habit...
  50. ncbi request reprint Effects of exercise training on 5 inflammatory markers associated with cardiovascular risk
    Christopher J K Hammett
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 151:367.e7-367.e16. 2006
    ....
  51. ncbi request reprint Informed consent during the clinical emergency of acute myocardial infarction (HERO-2 consent substudy): a prospective observational study
    Barbara F Williams
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Lancet 361:918-22. 2003
    ..We aimed to assess whether patients with acute myocardial infarction could understand written and verbal information and whether they were competent to give autonomous informed consent to participate in a clinical trial...
  52. ncbi request reprint ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis
    Ruvin S Gabriel
    Green Lane Cardiovascular Service, Auckland City Hospital, Level 3, Building 32, Private Bag 92 024, Auckland 1030, New Zealand
    Expert Rev Cardiovasc Ther 5:851-7. 2007
    ..Enoxaparin is an appropriate choice for adjunctive therapy with fibrinolysis in patients with STEMI...
  53. ncbi request reprint Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction
    John K French
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiovasc Drugs 4:107-15. 2004
    ..The major benefit of direct thrombin inhibitors appears to be in patients undergoing PCI, particularly after STEMI...
  54. ncbi request reprint Cardiogenic shock from left ventricular dysfunction complicating an acute ST-elevation myocardial infarction
    Cheuk Kit Wong
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart Hosp J 7:33-8. 2009
    ..Adjunctive therapies have been disappointing. To further improve outcomes, earlier pre-emptive and preventive strategies to ensure early revascularization should be pursued...
  55. ncbi request reprint Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study
    Ralph A Stewart
    Green Lane Cardiovascular Unit, Auckland City Hospital, Private Bag 92024, Auckland 1030, New Zealand
    N Z Med J 121:11-23. 2008
    ..This study describes differences in cardiovascular risk factors and cardiovascular mortality in Australians and New Zealanders with stable coronary artery disease stratified by socioeconomic status...
  56. ncbi request reprint Depression and cardiovascular morbidity and mortality: cause or consequence?
    Ralph A H Stewart
    Green Lane Hospital, Auckland, New Zealand
    Eur Heart J 24:2027-37. 2003
    ..This study assessed whether depressive symptoms were associated with adverse outcomes in people with a history of an acute coronary syndrome, and evaluated possible explanations for such an association...
  57. doi request reprint A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Am Heart J 156:348-55. 2008
    ..Effects of eplerenone on LV diastolic function and progression of valve stenosis were also evaluated...
  58. ncbi request reprint A score predicts failure of reperfusion after fibrinolytic therapy for acute myocardial infarction
    John K French
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand, Montreal Heart Institute, Montreal, Quebec, Canada
    Am Heart J 145:508-14. 2003
    ....
  59. ncbi request reprint Potential thrombophilic mutations/polymorphisms in patients with no flow-limiting stenosis after myocardial infarction
    John K French
    Department of Molecular Medicine, University of Auckland, Auckland, New Zealand
    Am Heart J 145:118-24. 2003
    ..Although inherited thrombophilias are more common in patients with venous thromboembolism, their influence on the development of myocardial infarction (MI) requires clarification...
  60. doi request reprint Left ventricular systolic and diastolic function assessed by tissue Doppler imaging and outcome in asymptomatic aortic stenosis
    Ralph A H Stewart
    Green Lane Cardiovascular Research, Auckland City Hospital, Auckland, New Zealand
    Eur Heart J 31:2216-22. 2010
    ..This study aimed to determine whether tissue Doppler measures of LV systolic and/or diastolic function or echocardiographic LV hypertrophy are useful for risk stratifying asymptomatic patients with severe calcific AS...
  61. ncbi request reprint Relation of initial platelet counts to Thrombolysis In Myocardial Infarction-3 flow rates at 90 minutes after commencing fibrinolytic therapy in patients with acute myocardial infarction
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Hospital, Epsom, Auckland, New Zealand
    Am J Cardiol 90:54-7. 2002
  62. ncbi request reprint Early ST-segment recovery, infarct artery blood flow, and long-term outcome after acute myocardial infarction
    John K French
    Cardiovascular Research Unit, Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Am Heart J 143:265-71. 2002
    ..Early resolution of ST-segment deviation (ST recovery) on the postthrombolytic electrocardiograms and restoration of "normal" blood flow in the infarct-related artery are associated with improved outcomes after myocardial infarction (MI)...
  63. ncbi request reprint White blood cell count predicts reduction in coronary heart disease mortality with pravastatin
    Ralph A H Stewart
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Circulation 111:1756-62. 2005
    ....
  64. ncbi request reprint Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial
    Cheuk Kit Wong
    Cardiovascular Research Unit, Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92024, Auckland 1030, New Zealand
    Eur Heart J 27:21-8. 2006
    ..Bundle branch block (BBB) early during acute myocardial infarction (AMI) is often considered high risk for mortality. Little is known about how different BBB types influence prognosis...
  65. ncbi request reprint Acute myocardial infarction
    Harvey D White
    Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    Lancet 372:570-84. 2008
    ..This Seminar discusses the underlying pathophysiology, evolving perspectives on diagnosis, risk stratification, and the invasive and pharmacological management of myocardial infarction...
  66. ncbi request reprint Increased myocardial ischemia after food is not explained by endothelial dysfunction
    Colin Edwards
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    Am Heart J 144:E8. 2002
    ..The aim of this study was to determine whether greater myocardial ischemia after either a low-fat or a high-fat meal is associated with an increase in brachial artery endothelial dysfunction...
  67. ncbi request reprint Facilitated percutaneous coronary intervention: is this strategy ready for implementation?
    Derek P Chew
    Green Lane Cardiovascular Service, Auckland City Hospital, Private Bag 92 024, Auckland 1001, New Zealand
    Curr Cardiol Rep 7:235-41. 2005
    ..If results are positive, the clinical practice determinants required for the effective application of this strategy to the wider clinical community will need careful consideration...
  68. ncbi request reprint Relation of left ventricular sphericity to 10-year survival after acute myocardial infarction
    Selwyn P Wong
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiol 94:1270-5. 2004
    ..002), treadmill exercise duration (p = 0.004), biplane left ventricular sphericity index (p = 0.032), age (p = 0.043), and end-systolic volume index (p = 0.047), but not TIMI flow grade...
  69. ncbi request reprint Prospective evaluation of a chest pain pathway at Green Lane Hospital
    John J Edmond
    Cardiovascular Research Unit, Green Lane Hospital, Auckland, New Zealand
    N Z Med J 115:U103. 2002
    ..To prospectively evaluate the efficacy and safety of a chest pain pathway at Green Lane Hospital...
  70. ncbi request reprint A case of cardiogenic shock caused by capecitabine treatment
    Andrew C Y To
    Green Lane Cardiovascular Service, Auckland City Hospital, Park Road, Grafton, Auckland 1023, New Zealand
    Nat Clin Pract Cardiovasc Med 5:725-9. 2008
    ..Five days into the first course, after initially experiencing diarrhea, nausea, vomiting and a transient episode of retrosternal chest pain radiating to the left scapula, she presented to the emergency department with cardiogenic shock...
  71. ncbi request reprint Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis
    Ivor L Gerber
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Circulation 107:1884-90. 2003
    ..This study assessed the associations between natriuretic peptide levels, disease severity, and cardiac symptoms in aortic stenosis...
  72. ncbi request reprint Associations between plasma natriuretic peptide levels, symptoms, and left ventricular function in patients with chronic aortic regurgitation
    Ivor L Gerber
    Cardiology Department, Green Lane Hospital, Auckland 1030 32, New Zealand
    Am J Cardiol 92:755-8. 2003
    ..In patients with chronic aortic regurgitation, measurement of natriuretic peptide levels may provide information on left ventricular function in addition to echocardiography...
  73. ncbi request reprint Effect of aortic valve replacement on c-reactive protein in nonrheumatic aortic stenosis
    Ivor L Gerber
    Cardiology Department, Green Lane Hospital, Auckland, New Zealand
    Am J Cardiol 92:1129-32. 2003
    ..C-reactive protein decreased from before to 6 months after aortic valve replacement for aortic stenosis. These observations suggest that aortic stenosis is an inflammatory disease...
  74. ncbi request reprint Society's expectation of the role of the doctor in New Zealand: results of a national survey
    Andrew Old
    Auckland City Hospital, Auckland 1142, New Zealand
    N Z Med J 124:10-22. 2011
    ..To describe the perceptions of the New Zealand public as to the role of the doctor in 2010...
  75. ncbi request reprint The impact of anthropomorphic indices on clinical outcomes in patients with acute ST-elevation myocardial infarction
    Rajendra H Mehta
    Duke Clinical Research Institute and Duke University Medical Center, PO Box 17969, Durham, NC 27715, USA, and Greenlane Cardiovascular Service, Auckland City Hospital, New Zealand
    Eur Heart J 28:415-24. 2007
    ..However, the relative prognostic importance of these measures over other baseline variables is less known...
  76. ncbi request reprint Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial
    Sana M Al-Khatib
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 145:515-21. 2003
    ..We studied the incidence, timing, and outcomes of such arrhythmias in the international Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries (GUSTO)-III trial...
  77. ncbi request reprint VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context
    Eric J Velazquez
    Division of Cardiology, Department of Medicine, Duke University Medical Center and the Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715, USA
    Eur J Heart Fail 5:537-44. 2003
    ....
  78. ncbi request reprint Functional status and quality of life after emergency revascularization for cardiogenic shock complicating acute myocardial infarction
    Lynn A Sleeper
    New England Research Institutes, Watertown, Massachusetts 02472, USA
    J Am Coll Cardiol 46:266-73. 2005
    ....
  79. ncbi request reprint Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thro
    Elliott M Antman
    TIMI Study Group, Boston, MA 02115, USA
    Am Heart J 149:217-26. 2005
  80. ncbi request reprint Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy
    Trip J Meine
    Division of Cardiology, Department of Medicine, Duke University, Durham, NC 27715, USA
    Am Heart J 149:670-4. 2005
    ..We sought to delineate predictors of AVB and determine long-term mortality of patients developing AVB in the setting of ST-segment elevation MI (STEMI) treated with thrombolytic therapy...
  81. ncbi request reprint Statin use and sex-specific stroke outcomes in patients with vascular disease
    Cheryl D Bushnell
    Center for Cerebrovascular Disease, Duke University Medical Center, Durham, NC 27710, USA
    Stroke 37:1427-31. 2006
    ..We investigated the relationships between statin use and sex-specific stroke incidence, severity, and mortality...
  82. ncbi request reprint Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin
    Harvey D White
    Am Heart J 143:189-92. 2002
  83. ncbi request reprint Cardiogenic shock: predictors of outcome based on right and left ventricular size and function at presentation
    Lisa A Mendes
    Boston Medical Center, Massachusetts, USA
    Coron Artery Dis 16:209-15. 2005
    ....
  84. ncbi request reprint Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes
    Kenneth W Mahaffey
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27715, USA
    Am J Cardiol 95:1404-8. 2005
    ..All MI types were associated with worse short- and long-term outcomes. Characterization of the type of MI provides an opportunity for more informed interpretation of clinical trial results and improved planning for future trials...
  85. ncbi request reprint Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
    Karolina E Szummer
    Department of Cardiology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Eur Heart J 26:2114-9. 2005
    ..We sought to assess the relative contribution of heart failure (HF) on admission for an acute myocardial infarction (MI) to the subsequent in-hospital stroke risk...
  86. ncbi request reprint Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction
    Nagesh S Anavekar
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 351:1285-95. 2004
    ..Renal failure is associated with one of the highest risks, but the influence of milder degrees of renal impairment is less well defined...
  87. ncbi request reprint Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective?
    Paul P Glasziou
    c Professor John Simes, NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW 1450, Australia
    Med J Aust 177:428-34. 2002
    ..To measure the cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with established ischaemic heart disease and average baseline cholesterol levels...
  88. ncbi request reprint Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial
    Brahmajee K Nallamothu
    University of Michigan Medical Center, Ann Arbor, MI, USA
    Eur Heart J 26:1506-12. 2005
    ....
  89. ncbi request reprint Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
    A Michael Lincoff
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195, USA
    JAMA 288:2130-5. 2002
    ..Rates of nonfatal ischemic complications were significantly diminished...
  90. ncbi request reprint Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B)
    Debabrata Mukherjee
    University of Michigan Health System, Ann Arbor, Mich, USA
    Am Heart J 144:995-1002. 2002
    ..Minimal data are available on LMWH combined with platelet glycoprotein (GP) IIb/IIIa inhibitors...
  91. ncbi request reprint Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: the ACUTE II study. The Antithrombotic Combination Using Tirofiban and
    Marc Cohen
    MCP Hahnemann University School of Medicine, Philadelphia, PA, USA
    Am Heart J 144:470-7. 2002
    ..Replacing UFH with enoxaparin when tirofiban is administered to patients may offer further therapeutic benefit, but could also increase bleeding...
  92. ncbi request reprint The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial
    Marc Cohen
    Newark Beth Israel Medical Center, Newark, New Jersey 07112, USA
    J Am Coll Cardiol 42:1348-56. 2003
    ....
  93. ncbi request reprint Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale
    Gregg W Stone
    Columbia University Medical Center, Cardiovascular Research Foundation, New York, NY 10022, USA
    Am Heart J 148:764-75. 2004
    ..Pilot trials suggest that the thrombin-specific anticoagulant bivalirudin may improve clinical outcomes in ACS...
  94. ncbi request reprint Drug insight: Statin use in the elderly
    O Christopher Raffel
    Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Nat Clin Pract Cardiovasc Med 3:318-28. 2006
    ..In this review we evaluate the evidence for statin use in this important and increasingly large group of patients...
  95. ncbi request reprint Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    Lancet 369:907-19. 2007
    ..The aim of this study was to assess anticoagulation with the direct thrombin inhibitor bivalirudin during percutaneous coronary intervention in individuals with moderate and high-risk acute coronary syndromes...
  96. ncbi request reprint Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience
    Kent Stephenson
    Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Heart Rhythm 4:308-13. 2007
    ....
  97. ncbi request reprint Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndrome
    Hassan Kassem-Moussa
    Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 148:439-46. 2004
    ..Stroke is a rare but serious event that complicates the course of patients with acute coronary syndromes (ACS). The type, outcome, and risk factors of stroke occurring in stabilized patients with ACS have not been previously reported...
  98. ncbi request reprint Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Rajesh Janardhanan
    Division of Cardiology, Brigham and Women s Hospital, Boston, MA02115, USA
    Am Heart J 152:183-9. 2006
    ..It is not known, however, whether the extent of coronary artery disease (CAD) independently influences cardiovascular (CV) outcomes in these high-risk patients...
  99. ncbi request reprint Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal
    Warren J Cantor
    Division of Cardiology, St Michael s Hospital, University of Toronto, Toronto, Ontario, Canada
    Catheter Cardiovasc Interv 69:73-83. 2007
    ..Our objective was to analyze the impact of arterial access site, sheath size, timing of sheath removal, and use of access site closure devices on high-risk patients with acute coronary syndromes (ACS)...
  100. ncbi request reprint Bivalirudin for patients with acute coronary syndromes
    Gregg W Stone
    Columbia University Medical Center and the Cardiovascular Research Foundation, New York, NY 10022, USA
    N Engl J Med 355:2203-16. 2006
    ..We evaluated the role of thrombin-specific anticoagulation with bivalirudin in such patients...
  101. ncbi request reprint Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention
    Gilles Montalescot
    Institut de Cardiologie, Centre Hospitalier Universitaire Pitie Salpetriere, Paris, France
    N Engl J Med 355:1006-17. 2006
    ..Several small studies have suggested that intravenous enoxaparin may be a safe and effective alternative. Our primary aim was to assess the safety of enoxaparin as compared with that of unfractionated heparin in elective PCI...